Features of fecal microbiota at baseline and after antibiotic therapy may be predictive of recurrent Clostridiodes difficile infection in patients with and without ulcerative colitis.
A glutamate dehydrogenase test for Clostridioides difficile may reduce unnecessary isolation time for patients.
The FDA has approved fidaxomicin for the treatment of Clostridioides difficile-associated diarrhea in adult and pediatric patients aged 6 months and older.
Clostridioides difficile infection is associated with a large burden on the healthcare system in the United States.
Dual therapy with intravenous metronidazole and oral vancomycin is not superior to oral vancomycin alone in the treatment of Clostridioides difficile infections.
Asymptomatic carriers of C. difficile at significant risk for progression to symptomatic infection
Toxin enzyme immunoassay more accurately identifies severe C difficile infections from strains more likely to cause recurrence, but otherwise had similar results for complications and mortality compared with the standard nucleic acid amplification test.
Patients with recurrent Clostridioides difficile infection (CDI) were less likely to develop bloodstream infections (BSI) if treated with fecal microbiota transplantation (FMT) compared with antibiotics.
Studies present promising therapeutic options to reduce recurrent CDI, as well as strategies to improve favorable economic outcomes.
Detection of Clostridioides difficile toxins in fecal matter can lead to accurate diagnosis of C difficile infection.
Direct costs come from extended length of stay and increased hospitalization costs
Repeat testing of nucleic acid amplification tests is not recommended for detection of the presence of Clostridioides (formerly Clostridium) difficile in adults.
The use of a nucleic acid assay (NAAT) for diagnosing Clostridium difficile infection demonstrated a significant reduced length of stay (LOS) for patients compared with a multi-step enzyme immunoassay-based strategy, according to data presented at the American Society for Microbiology (ASM) Microbe 2019, held in San Francisco, California, from June 20 to 24, 2019. C…
Fecal microbiota transplantation is a still-experimental procedure, as yet unapproved by the FDA
Facility-level rates of hospital-onset Clostridioides difficile infection have been found to decrease correspondingly with lower usage of antibiotics.
The combination of vancomycin and fecal microbiota transplantation was found to be superior to fidaxomicin or vancomycin for patients with recurrent CDI.
The FDA has granted Breakthrough Therapy designation to CP101 for the treatment of patients with recurrent Clostridium difficile.
Aemcolo is a broad spectrum, semi-synthetic, orally-administered, minimally-absorbed antibiotic designed to allow for delayed release to the colon.
Oral vancomycin is effective in preventing C difficile infection in allogeneic hematopoietic cell transplant patients and does not raise the risk for GVHD.
Patients admitted from the community who are hospitalized with Clostridioides (formerly Clostridium) difficile infection were more frequently discharged to a non-home location compared to patients without C difficile infection.